Fragment
Fragment Bio is developing a rapid biosensing technology that detects molecular fragments to screen for cancers, pathogens, and contaminants. The platform is benchmarked against current gold standards to deliver faster, more accessible biomarker data for screening and diagnostic applications. Its technology aims to expand precision health capabilities beyond traditional laboratory-based testing.
- Artificial Intelligence
- Biotechnology
- Hardware
- Healthcare Technology
- Medical Devices
Funding
Founders
Product
Problem
Traditional biomarker detection for cancer, pathogen, and contaminant screening typically requires laboratory-based equipment, lengthy processing times, and specialized personnel, limiting rapid and accessible testing. This constrains early detection efforts and delays actionable diagnostic information, particularly in point-of-care or resource-limited settings.
Solution
Fragment Bio is developing an innovative biosensing technology that detects molecular fragments—such as DNA, RNA, or protein fragments—as biomarkers for a wide range of conditions, including cancers, pathogens, and environmental contaminants. The platform is designed to deliver rapid results while being carefully benchmarked against current gold-standard methods to ensure accuracy and reliability. By measuring these fragment-based biomarkers with a novel sensing approach, the company aims to shift biomarker data collection toward faster, more portable, and more accessible formats. The technology is positioned to disrupt existing diagnostic workflows by enabling screening and monitoring outside traditional laboratory environments.
Target Audience
Primary customers include clinical diagnostics providers, hospitals, and point-of-care testing developers seeking rapid biomarker screening solutions, as well as public health and environmental monitoring organizations needing on-site contaminant or pathogen detection.
Features
- Fragment-based biomarker detection technology capable of identifying cancers, pathogens, and contaminants
- Sensing platform engineered for portability and wearable or point-of-care integration, reducing reliance on centralized lab infrastructure
- Rapid measurement capability designed to accelerate time-to-result compared with conventional diagnostic workflows
- Benchmarking against established gold-standard assays to validate accuracy and clinical relevance
- Versatile application across multiple biomarker classes, including genomics and virology use cases